Henry Schein, Inc. (NASDAQ: HSIC) Stock Competitors & Peer Comparison
See HSIC's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HSIC and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HSIC | $88.47 | -0.92% | 10.1B | 16.66 | $5.31 | N/A |
| MCK | $863.20 | +1.11% | 98.2B | 20.55 | $40.82 | +0.39% |
| COR | $319.18 | +0.66% | 61.2B | 18.35 | $17.15 | +0.76% |
| CAH | $228.91 | -2.53% | 53.5B | 21.90 | $10.43 | +0.89% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +2.49% |
| PBH | $50.93 | -1.45% | 2.4B | 11.43 | $4.42 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
| ACH | $1.24 | -6.44% | 99.9M | 1.92 | $0.68 | N/A |
| HX | $2.24 | -4.27% | 53.4M | -1.84 | -$1.22 | N/A |
Stock Comparison
McKesson Corporation (NYSE: MCK)
HSIC vs MCK Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, MCK has a market cap of 98.2B. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while MCK trades at $863.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas MCK's P/E ratio is 20.55. In terms of profitability, HSIC's ROE is +0.12%, compared to MCK's ROE of -1.94%. Regarding short-term risk, HSIC is less volatile compared to MCK. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check MCK's competition here
Cencora, Inc. (NYSE: COR)
HSIC vs COR Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, COR has a market cap of 61.2B. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while COR trades at $319.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas COR's P/E ratio is 18.35. In terms of profitability, HSIC's ROE is +0.12%, compared to COR's ROE of +1.06%. Regarding short-term risk, HSIC is less volatile compared to COR. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check COR's competition here
Cardinal Health, Inc. (NYSE: CAH)
HSIC vs CAH Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, CAH has a market cap of 53.5B. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while CAH trades at $228.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas CAH's P/E ratio is 21.90. In terms of profitability, HSIC's ROE is +0.12%, compared to CAH's ROE of -0.60%. Regarding short-term risk, HSIC is less volatile compared to CAH. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check CAH's competition here
AmerisourceBergen Corporation (NYSE: ABC)
HSIC vs ABC Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas ABC's P/E ratio is 21.92. In terms of profitability, HSIC's ROE is +0.12%, compared to ABC's ROE of +1.06%. Regarding short-term risk, HSIC is more volatile compared to ABC. This indicates higher risk in terms of short-term price fluctuations for HSIC.Check ABC's competition here
Patterson Companies, Inc. (NASDAQ: PDCO)
HSIC vs PDCO Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas PDCO's P/E ratio is 20.48. In terms of profitability, HSIC's ROE is +0.12%, compared to PDCO's ROE of +0.18%. Regarding short-term risk, HSIC is more volatile compared to PDCO. This indicates higher risk in terms of short-term price fluctuations for HSIC.Check PDCO's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
HSIC vs PBH Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, PBH has a market cap of 2.4B. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while PBH trades at $50.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas PBH's P/E ratio is 11.43. In terms of profitability, HSIC's ROE is +0.12%, compared to PBH's ROE of +0.09%. Regarding short-term risk, HSIC is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check PBH's competition here
Owens & Minor, Inc. (NYSE: OMI)
HSIC vs OMI Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas OMI's P/E ratio is -0.47. In terms of profitability, HSIC's ROE is +0.12%, compared to OMI's ROE of +0.63%. Regarding short-term risk, HSIC is less volatile compared to OMI. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check OMI's competition here
Accendra Health, Inc. (NYSE: ACH)
HSIC vs ACH Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, ACH has a market cap of 99.9M. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while ACH trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas ACH's P/E ratio is 1.92. In terms of profitability, HSIC's ROE is +0.12%, compared to ACH's ROE of +0.63%. Regarding short-term risk, HSIC is less volatile compared to ACH. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check ACH's competition here
Akso Health Group (NASDAQ: HX)
HSIC vs HX Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas HX's P/E ratio is -1.84. In terms of profitability, HSIC's ROE is +0.12%, compared to HX's ROE of -1.07%. Regarding short-term risk, HSIC is less volatile compared to HX. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check HX's competition here
111, Inc. (NASDAQ: YI)
HSIC vs YI Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, YI has a market cap of 29.8M. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while YI trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas YI's P/E ratio is -2.44. In terms of profitability, HSIC's ROE is +0.12%, compared to YI's ROE of +0.14%. Regarding short-term risk, HSIC is less volatile compared to YI. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check YI's competition here
Wellgistics Health, Inc. (NASDAQ: WGRX)
HSIC vs WGRX Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, WGRX has a market cap of 8.7M. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while WGRX trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas WGRX's P/E ratio is -0.33. In terms of profitability, HSIC's ROE is +0.12%, compared to WGRX's ROE of +8.78%. Regarding short-term risk, HSIC is less volatile compared to WGRX. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check WGRX's competition here
ZeroStack Corp. (NASDAQ: ZSTK)
HSIC vs ZSTK Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, ZSTK has a market cap of 6.2M. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while ZSTK trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas ZSTK's P/E ratio is -0.12. In terms of profitability, HSIC's ROE is +0.12%, compared to ZSTK's ROE of -3.82%. Regarding short-term risk, HSIC is less volatile compared to ZSTK. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check ZSTK's competition here
DataMEDS AI, Inc. (NASDAQ: MEDS)
HSIC vs MEDS Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, MEDS has a market cap of 3.8M. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while MEDS trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas MEDS's P/E ratio is N/A. In terms of profitability, HSIC's ROE is +0.12%, compared to MEDS's ROE of +8.78%. Regarding short-term risk, HSIC is less volatile compared to MEDS. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check MEDS's competition here
Zynex, Inc. (NASDAQ: ZYXI)
HSIC vs ZYXI Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, HSIC's ROE is +0.12%, compared to ZYXI's ROE of +11.38%. Regarding short-term risk, HSIC is more volatile compared to ZYXI. This indicates higher risk in terms of short-term price fluctuations for HSIC.Check ZYXI's competition here
Synergy CHC Corp. (NASDAQ: SNYR)
HSIC vs SNYR Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, SNYR has a market cap of 1.2M. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while SNYR trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas SNYR's P/E ratio is -0.08. In terms of profitability, HSIC's ROE is +0.12%, compared to SNYR's ROE of +0.91%. Regarding short-term risk, HSIC is less volatile compared to SNYR. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check SNYR's competition here
Ridgetech, Inc. (NASDAQ: RDGT)
HSIC vs RDGT Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, RDGT has a market cap of 724.3K. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while RDGT trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas RDGT's P/E ratio is -0.01. In terms of profitability, HSIC's ROE is +0.12%, compared to RDGT's ROE of -0.04%. Regarding short-term risk, HSIC is less volatile compared to RDGT. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check RDGT's competition here
Covetrus, Inc. (NASDAQ: CVET)
HSIC vs CVET Comparison August 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10.1B. In comparison, CVET has a market cap of 0. Regarding current trading prices, HSIC is priced at $88.47 on the NASDAQ, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.66, whereas CVET's P/E ratio is -69.97. In terms of profitability, HSIC's ROE is +0.12%, compared to CVET's ROE of -0.06%. Regarding short-term risk, HSIC is more volatile compared to CVET. This indicates higher risk in terms of short-term price fluctuations for HSIC.Check CVET's competition here